Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Expenses (2020 - 2025)

Silence Therapeutics' Operating Expenses history spans 6 years, with the latest figure at $31.4 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 31.28% to $31.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.9 million, a 381.96% increase, with the full-year FY2025 number at $91.4 million, up 584.74% from a year prior.
  • Operating Expenses hit $31.4 million in Q4 2025 for Silence Therapeutics, up from $18.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for SLN hit a ceiling of $143.1 million in Q4 2023 and a floor of -$15.5 billion in Q1 2021.
  • Historically, Operating Expenses has averaged -$758.2 million across 5 years, with a median of -$10.5 million in 2022.
  • Biggest five-year swings in Operating Expenses: tumbled 99.58% in 2021 and later soared 187.57% in 2025.
  • Tracing SLN's Operating Expenses over 5 years: stood at $119.9 million in 2021, then dropped by 3.54% to $115.6 million in 2022, then grew by 23.76% to $143.1 million in 2023, then tumbled by 68.05% to $45.7 million in 2024, then tumbled by 31.28% to $31.4 million in 2025.
  • Business Quant data shows Operating Expenses for SLN at $31.4 million in Q4 2025, $18.9 million in Q3 2025, and $3.4 million in Q2 2025.